Oncologists Choose Top Goals and Therapies for Treating MDS

Myelodysplastic syndrome (MDS) is a heterogeneous clonal hematologic neoplasm defined by cytopenias, dysplasia, and clonal cytogenetic and molecular abnormalities.¹ The heterogeneity is evident in that prognosis can range from months to over 10 years, depending on the features of the MDS. Therefore, making the diagnosis and risk stratification as precise as possible is imperative in the selection of treatment.